Erratum to: "Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone" (DOI:10.1016/j.rmed.2007.07.014);Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone

Respiratory Medicine

Volumn 101, Issue 12, 2007, Pages 2437-2446

  Bousquet, Jean ^a   Boulet, Louis Philippe ^b   Peters, Matthew J ^c   Magnussen, Helgo ^d   Quiralte, Joaquin ^e   Martinez Aguilar, Nora E ^f   Carlsheimer, Åsa ^g  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b LAVAL UNIVERSITY   (Canada)

^c Department of Microbiology and Infectious Diseases   (Australia)

^d KRANKENHAUS GROSSHANSDORF   (Germany)

^e Medical Oncology Department   (Spain)

^f HOSPITAL REGIONAL 1 DE OCTUBRE   (Mexico)

^g ASTRAZENECA R AND D   (Sweden)

Author keywords

Asthma control; Combination therapy; Exacerbations; Hospitalisations; Maintenance plus as needed

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; STEROID; TERBUTALINE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHONIA; EMERGENCY CARE; FEMALE; FORCED EXPIRATORY VOLUME; HEART PALPITATION; HOSPITALIZATION; HUMAN; INCIDENCE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TACHYCARDIA; THRUSH; TREMOR;

EID: 35548946304     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2007.11.006     Document Type: Erratum

References (35)

1. Bousquet J., Clark T.J., Hurd S., et al. GINA guidelines on asthma and beyond. Allergy 62 (2007) 102-112
2. Humbert M., Holgate S., Boulet L.P., and Bousquet J. Asthma control or severity: that is the question. Allergy 62 (2007) 95-101
3. Partridge M.R., van der Molen T., Myrseth S.E., and Busse W.W. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 6 (2006) 13
4. Rabe K.F., Adachi M., Lai C.K., et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 114 (2004) 40-47
5. Angus R., Reagon R., and Cheesbrough A. Short-acting beta 2-agonist and oral corticosteroid use in asthma patients prescribed either concurrent beclomethasone and long-acting beta 2-agonist or salmeterol/fluticasone propionate combination. Int J Clin Pract 59 (2005) 156-162
6. Global Initiative for Asthma. Global strategy for asthma management and prevention, 2006. Available at: 〈http://www.ginasthma.com〉.
7. Bateman E.D., Boushey H.A., Bousquet J., et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 170 (2004) 836-844
8. O'Byrne P.M., Barnes P.J., Rodriguez-Roisin R., et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 164 (2001) 1392-1397
9. Pauwels R.A., Lofdahl C.G., Postma D.S., et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 337 (1997) 1405-1411
10. NIH Publication No 97-4051. National Asthma Education and Prevention Program Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Available at: 〈http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm〉.
11. British Thoracic Society and Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma. A national clinical guideline, 2005. Available at: 〈http://www.brit-thoracic.org.uk/〉.
12. Lai C.K., De Guia T.S., Kim Y.Y., et al. Asthma control in the Asia-Pacific region: the Asthma Insights and Reality in Asia-Pacific Study. J Allergy Clin Immunol 111 (2003) 263-268
13. Anderson H.R., Ayres J.G., Sturdy P.M., et al. Bronchodilator treatment and deaths from asthma: case-control study. BMJ 330 (2005) 117
14. Lanes S.F., Garcia Rodriguez L.A., and Huerta C. Respiratory medications and risk of asthma death. Thorax 57 (2002) 683-686
15. Palmqvist M., Persson G., Lazer L., Rosenborg J., Larsson P., and Lotvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 10 (1997) 2484-2489
16. Pauwels R.A., Sears M.R., Campbell M., et al. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J 22 (2003) 787-794
17. O'Byrne P.M., Bisgaard H., Godard P.P., et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 171 (2005) 129-136
18. Rabe K.F., Atienza T., Magyar P., Larsson P., Jorup C., and Lalloo U.G. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 368 (2006) 744-753
19. Vogelmeier C., D'Urzo A., Pauwels R., et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?. Eur Respir J 26 (2005) 819-828
20. Kuna P., Peters M.J., Manjra A.I., et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 61 (2007) 725-736
21. Sin D.D., Man J., Sharpe H., Gan W.Q., and Man S.F. Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. JAMA 292 (2004) 367-376
22. Juniper E.F., Svensson K., Mork A.C., and Stahl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 99 (2005) 553-558
23. Harrison T.W., Oborne J., Newton S., and Tattersfield A.E. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 363 (2004) 271-275
24. FitzGerald J.M., Becker A., Sears M.R., Mink S., Chung K., and Lee J. Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax 59 (2004) 550-556
25. Barnes P.J. Scientific rationale for using a single inhaler for asthma control. Eur Respir J 29 (2007) 587-595
26. Gibson P.G., Saltos N., and Fakes K. Acute anti-inflammatory effects of inhaled budesonide in asthma. A randomized controlled trial. Am J Respir Crit Care Med 163 (2001) 32-36
27. Mendes E.S., Pereira A., Danta I., Duncan R.C., and Wanner A. Comparative bronchial vasoconstrictive efficacy of inhaled glucocorticosteroids. Eur Respir J 21 (2003) 989-993
28. Paredi P., Kharitonov S.A., and Barnes P.J. Correlation of exhaled breath temperature with bronchial blood flow in asthma. Respir Res 6 (2005) 15
29. Duong M., Gauvreau G., Watson R., et al. The effects of inhaled budesonide and formoterol in combination and alone when given directly after allergen challenge. J Allergy Clin Immunol 119 (2007) 322-327
30. Tattersfield A.E., Lofdahl C.G., Postma D.S., et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet 357 (2001) 257-261
31. Palmqvist M., Ibsen T., Mellen A., and Lotvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 160 (1999) 244-249
32. FitzGerald J.M., and Gibson P.G. Asthma exacerbations-4: prevention. Thorax 61 (2006) 992-999
33. Edwards S.J., Gruffydd-Jones K., and Ryan D.P. Systematic review and meta-analysis of budesonide/formoterol in a single inhaler. Curr Med Res Opin 23 (2007) 1809-1820
34. van Veen A., Weller F.R., Wierenga E.A., Jansen H.M., and Jonkers R.E. A comparison of salmeterol and formoterol in attenuating airway responses to short-acting beta2-agonists. Pulm Pharmacol Ther 16 (2003) 153-161
35. Tintinger G.R., Anderson R., Theron A.J., Ramafi G., and Ker J.A. Comparison of the effects of selective and non-selective beta-adrenoceptor agonists on the pro-inflammatory activities of human neutrophils in vivo. Inflammation 24 (2000) 239-249